Evidence map›Paper›PMID 31438847›Full record

ArticleBMC bioinformatics2019

Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line.

Claus Weinholdt, Henri Wichmann, Johanna Kotrba, David H Ardell, Matthias Kappler, Alexander W Eckert, Dirk Vordermark, Ivo Grosse

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Claus WeinholdtInstitute of Computer Science, Martin Luther University Halle-Wittenberg, Halle, Germany. claus.weinholdt@informatik.uni-halle.de.ORCID http://orcid.org/0000-0002-0546-5232
Henri WichmannDepartment of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, Halle, Germany.
Johanna KotrbaDepartment of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, Halle, Germany.
David H ArdellMolecular Cell Biology, School of Natural Sciences, University of California, Merced, USA.
Matthias KapplerDepartment of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, Halle, Germany.
Alexander W EckertDepartment of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, Halle, Germany.
Dirk VordermarkDepartment of Radiotherapy, Martin Luther University Halle-Wittenberg, Halle, Germany.
Ivo GrosseInstitute of Computer Science, Martin Luther University Halle-Wittenberg, Halle, Germany.
Martin Luther University Halle-Wittenberg · DEGerman Centre for Integrative Biodiversity Research · DEUniversity of California, Merced · US

Funding

Bundesministerium für Bildung und Forschung FKZ: 16/18, 19/13, 21/25Bundesministerium für Bildung und Forschung (DE) FKZ: 16/18, 19/13, 21/25Bundesministerium für Bildung und Forschung (DE) FKZ 24/19Deutsche Forschungsgemeinschaft (DE) project number 197267875 - grant number GR 3526/2Deutsche Forschungsgemeinschaft (DE) project number 251444481 - grant number GR 3526/6
6 · The paper itself

Abstract

backgroundThe epidermal growth factor receptor (EGFR) is a major regulator of proliferation in tumor cells. Elevated expression levels of EGFR are associated with prognosis and clinical outcomes of patients in a variety of tumor types. There are at least four splice variants of the mRNA encoding four protein isoforms of EGFR in humans, named I through IV. EGFR isoform I is the full-length protein, whereas isoforms II-IV are shorter protein isoforms. Nevertheless, all EGFR isoforms bind the epidermal growth factor (EGF). Although EGFR is an essential target of long-established and successful tumor therapeutics, the exact function and biomarker potential of alternative EGFR isoforms II-IV are unclear, motivating more in-depth analyses. Hence, we analyzed transcriptome data from glioblastoma cell line SF767 to predict target genes regulated by EGFR isoforms II-IV, but not by EGFR isoform I nor other receptors such as HER2, HER3, or HER4.

resultsWe analyzed the differential expression of potential target genes in a glioblastoma cell line in two nested RNAi experimental conditions and one negative control, contrasting expression with EGF stimulation against expression without EGF stimulation. In one RNAi experiment, we selectively knocked down EGFR splice variant I, while in the other we knocked down all four EGFR splice variants, so the associated effects of EGFR II-IV knock-down can only be inferred indirectly. For this type of nested experimental design, we developed a two-step bioinformatics approach based on the Bayesian Information Criterion for predicting putative target genes of EGFR isoforms II-IV. Finally, we experimentally validated a set of six putative target genes, and we found that qPCR validations confirmed the predictions in all cases.

conclusionsBy performing RNAi experiments for three poorly investigated EGFR isoforms, we were able to successfully predict 1140 putative target genes specifically regulated by EGFR isoforms II-IV using the developed Bayesian Gene Selection Criterion (BGSC) approach. This approach is easily utilizable for the analysis of data of other nested experimental designs, and we provide an implementation in R that is easily adaptable to similar data or experimental designs together with all raw datasets used in this study in the BGSC repository, https://github.com/GrosseLab/BGSC .

Indexed as

Alternative SplicingBayes TheoremCell Line, TumorComputational BiologyErbB ReceptorsGlioblastomaHumansProbabilityProtein IsoformsRNA InterferenceRNA, Small InterferingSignal TransductionErbB ReceptorsProtein IsoformsRNA, Small InterferingBayesian Gene Selection CriterionBayesian Information CriterionEGFRRNAiSplice variants

Identifiers

PMID31438847
PMCPMC6704634
OpenAlexW2969519747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.